Study

Overview

Official Title: A Two-Period, Open-label, Fixed-Sequence Study to Evaluate the Single-Dose Pharmacokinetics of Two Formulations of MK-1167 in Healthy Participants

Researchers are looking for new ways to treat Alzheimer’s disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine. The goals of the trial are to learn: • What happens to different forms of MK-1167 in a healthy person’s body over time • About the safety of MK-1167 and if people tolerate it

Study Type:

Interventional

Study Phase:

Phase 1

Estimated Enrollment:

16

Study Start Date:

February 2026

Estimated Study Completion Date:

May 2026

Estimated Primary Completion Date:

May 2026

Eligibility

Ages Eligible for Study:

18 years to 60 years

Genders Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

CRITERIA

Inclusion Criteria:

Is in good health
Has a body mass index (BMI) ≥18 and ≤ 32 kg/m^2, inclusive

Exclusion Criteria:

Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months.

Locations

No Contacts or Locations in US/Canada Provided

Results

No Study Results Posted

Study Detail

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

Overview

Eligibility

CRITERIA

Locations

Results